Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.48 |
| ▸ | CDK1 | P06493 | 6/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.39 |
| ▸ | MGMT | P16455 | 3/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658526 | 0.82 | CDK2 (0.52) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL439475 | 0.79 | CDK2 (0.61) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL11121357 | 0.73 | CDK2 (0.55) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL21158500 | 0.71 | CDK2 (0.53) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL29473573 | 0.70 | CDK2 (0.52) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL4160357 | 0.70 | CDK2 (0.52) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| Nitrous Acid SCHEMBL29168822 | 0.67 | CDK2 (0.48) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL656566 | 0.67 | CDK2 (0.48) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL6209356 | 0.65 | CDK2 (0.52) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL9443788 | 0.65 | CDK2 (0.47) | CDK2CCNA2CCNA1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467996-B1 | PYRIMIDOTRIAZINES AS PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-11-30 | — | — | EP | disclosed |
| EP-1467996-A1 | PYRIMIDOTRIAZINES AS PHOSPHATASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-20 | — | — | EP | disclosed |
| US-6642381-B2 | Containing tertiary alkyl amine, pyrollidine, morpholine or piperazine moieties; optionally containing unsubstituted or substituted phenyl or naphthyl groups | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030153756-A1 | Pyrimido[5,4-e] [1,2,4]triazine-5, 7-diamine compounds as protein tyrosine phosphatase inhibitors | GUERTIN KEVIN RICHARD (US) | 2003-08-14 | — | — | US | disclosed |
| WO-2003055883-A1 | PYRIMIDOTRIAZINES AS PHOSPHATASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153756-A1 | Pyrimido[5,4-e] [1,2,4]triazine-5, 7-diamine compounds as protein tyrosine phosphatase inhibitors | PTPN5, PPP5C, PTPA | CDK2 190/4885CCNA2 1005/4885CCNA1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.